当前位置: X-MOL 学术Br. J. Haematol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Long-term outcome evaluation of medium/high risk acute lymphoblastic leukaemia children treated with or without cranial radiotherapy in the EORTC 58832 randomized study.
British Journal of Haematology ( IF 5.1 ) Pub Date : 2019-12-13 , DOI: 10.1111/bjh.16337
Caroline Piette 1 , Stefan Suciu 2 , Yves Bertrand 3 , Anne Uyttebroeck 4 , Els Vandecruys 5 , Geneviève Plat 6 , Catherine Paillard 7 , Claire Pluchart 8 , Nicolas Sirvent 9 , Renée Maurus 10 , Maryline Poirée 11 , Pauline Simon 12 , Alina Ferster 13 , Claire Hoyoux 1 , Françoise Mazingue 14 , Robert Paulus 15 , Claire Freycon 16 , Caroline Thomas 17 , Pierre Philippet 18 , Caroline Gilotay 2 , Jutte van der Werff Ten Bosch 19 , Pierre S Rohrlich 11 , Yves Benoit 5
Affiliation  

We investigated the long-term outcome, the incidence of second neoplasms (SN) and the rate of late adverse effects (LAE) in children with central nervous system (CNS) negative medium/high-risk de novo acute lymphoblastic leukaemia (ALL), in first complete remission (CR1) at end of late intensification, randomized to receive no cranial radiotherapy (No CRT, n = 92) versus CRT (standard arm, n = 84) in the non-inferiority EORTC 58832 study (1983-1989). Median follow-up was 20 years (range 4-32 years). The 25-year disease-free survival rate (±SE) was 67·4 ± 4·9% without CRT and 70·2 ± 5·0% with CRT. The 25-year incidence of isolated (6·5 ± 2·6% vs. 4·8 ± 2·3%) and any CNS relapse {8·7 ± 2·9% vs. 11·9 ± 3·5%; hazard ratio (HR) 0·71 [95% confidence interval (CI) 0·28-1·79]; test of non-inferiority: P = 0·01} was not increased without CRT. The 25-year SN incidence in CR1 was 7·9 ± 4·6% vs. 11·0 ± 4·2%. The 25-year event-free and overall survival rates were quite similar in both arms [59·5 ± 6·3% vs. 60·5 ± 5·9%, HR 0·94 (95% CI 0·57-1·52), and 78·1 ± 4·3% vs. 78·5 ± 4·5%, HR 1·00 (95% CI 0·53-1·88)]. Omission of CRT was associated with dramatic decrease in CNS and endocrine LAE rates. In conclusion, our data suggest that, with proper systemic and intrathecal CNS prophylaxis, CRT could totally be omitted in CR1 without jeopardizing survival, while decreasing LAE in childhood ALL.

中文翻译:

在EORTC 58832随机研究中,对接受或不接受颅脑放疗的中/高危急性淋巴细胞性白血病儿童进行了长期结局评估。

我们研究了中枢神经系统(CNS)阴性中/高危从头急性淋巴细胞性白血病(ALL)患儿的长期预后,第二肿瘤的发生率(SN)和晚期不良反应发生率(LAE),在非劣效性EORTC 58832研究(1983-1989)中,在晚期强化治疗结束后的首次完全缓解(CR1)中,随机接受不进行颅骨放疗(No CRT,n = 92)vs CRT(标准组,n = 84) 。中位随访时间为20年(范围4-32年)。不使用CRT的25年无病生存率(±SE)为67·4±4·9%,使用CRT的为70·2±5·0%。孤立的25年发生率(6·5±2·6%与4·8±2·3%)和任何中枢神经系统复发(8·7±2·9%与11·9±3·5% ; 危险比(HR)0·71 [95%置信区间(CI)0·28-1·79];非劣效性测试:没有CRT,P = 0·01}没有增加。CR1中25年的SN发生率为7·9±4·6%,而11·0±4·2%。两组的25年无事件生存率和总生存率非常相似[59·5±6·3%vs. 60·5±5·9%,HR 0·94(95%CI 0·57-1 ·52),以及78·1±4·3%和78·5±4·5%,HR 1·00(95%CI 0·53-1·88)。省略CRT与中枢神经系统和内分泌LAE率急剧下降有关。总之,我们的数据表明,通过适当的全身和鞘内中枢神经系统预防,可以完全消除CR1中的CRT,而不会危害生存,同时降低儿童ALL的LAE。省略CRT与中枢神经系统和内分泌LAE率急剧下降有关。总之,我们的数据表明,通过适当的全身和鞘内中枢神经系统预防,可以完全消除CR1中的CRT,而不会危害生存,同时降低儿童ALL的LAE。省略CRT与中枢神经系统和内分泌LAE率急剧下降有关。总之,我们的数据表明,通过适当的全身和鞘内中枢神经系统预防,可以完全消除CR1中的CRT,而不会危害生存,同时降低儿童ALL的LAE。
更新日期:2019-12-13
down
wechat
bug